Laura Fontan

FDA investigator

Appears on 8 documents from 2017 to 2022, most often at sites in California. Most often cites written procedures; deviations (21 CFR 211.100).

8
Documents on file
4.0
Observations per 483
2017
First seen
2022
Most recent

What they cite most

From 28 observations

Activity by year

2017: 2, 2018: 3, 2019: 1, 2021: 1, 2022: 1

Where

California 2 · Austria 1 · Belgium 1 · Florida 1 · India 1 · Ireland 1

Is Laura Fontan coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 BioMarin Pharmaceutical Inc.Dec 9, 2022 · Novato, California
EIR Pfizer Manufacturing Belgium NVJul 2, 2021 · Puurs, Belgium
483 CORERX, INC.Jun 14, 2019 · CLEARWATER, Florida
483 Biocon Limited Special Economic Zone, Plot No, 2-5, Phase IVMay 1, 2018 · Bangalore, India
483 Eli Lilly Kinsale LimitedMar 16, 2018 · Kinsale, Ireland
483 Sandoz GmbHFeb 20, 2018 · Langkampfen, Austria
483 Amgen, IncMay 16, 2017 · Thousand Oaks, California

About this profile

What does Laura Fontan inspect?

Laura Fontan appears on 8 documents on file covering 8 sites, most often in California.

What do they cite most often?

21 CFR 211.100 (written procedures; deviations), followed by 21 CFR 211.113 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Laura Fontan is dated Dec 9, 2022.

FDA Investigator Laura Fontan: 483s & Inspections · FDA Intel